Yuki Noguchi
Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C. She started covering consumer health in the midst of the pandemic, reporting on mental health, vaccination, telehealth, and racial inequities in healthcare.
Noguchi started her career as a reporter, then an editor, for The Washington Post, primarily covering business and technology. Noguchi joined NPR as a business correspondent in 2008, just before the financial crisis and Great Recession. She has covered a wide range of issues, from the workplace to the earthquake and tsunami in her parents' native Japan in 2011. Her coverage of the impact of opioids on workers and their families won a 2019 Gracie Award as well as First Place and Best In Show in the radio category from the National Headliner Awards. Her work on medical debt, in partnership with Kaiser Health News, won a 2023 Gerald Loeb award and an award from the National Institutes of Health Care Management.
Noguchi grew up in St. Louis, likes to cook, has a degree in history from Yale and is raising two boys and two rescue dogs outside Washington DC.
-
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs. -
Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message. -
The anti-parasitic drug became a household name during the COVID-19 pandemic, and it is now being embraced as an alternative treatment for cancer. It is as politically polarizing as ever. -
Easier than a blood test, saliva tests have the potential to detect cavities, infections and even cancer. But a lack of insurance coverage and other obstacles stand in the way of wider use. -
James Van Der Beek's death at age 48 highlights a sad statistic: More people under 50 are getting colorectal cancer.
-
Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want to lose a few pounds. -
Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders. -
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now. -
As GLP-1 drugs become more available, some people might use them despite not having excess weight.
-
Ivermectin's reputation keeps growing as a kind of cure-all, even for cancer — despite evidence it doesn't work.
